Mirum Pharmaceuticals Scheduled to Attend Upcoming Investor Conferences

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading biopharmaceutical firm specializing in the discovery, acquisition, development, and distribution of innovative therapies for rare and orphan diseases, has revealed its participation in forthcoming investor conferences as follows:

  1. Leerink Partners Global Biopharma Conference 2024:
    • Date: Tuesday, March 12, 2024
    • Company presentation: Tuesday, March 12, commencing at 3:00 p.m. ET
  2. Barclays Global Healthcare Conference 2024:
    • Date: Wednesday, March 13, 2024

For webcast links and additional details, interested parties are encouraged to visit the Investors and Media section on Mirum’s official corporate website.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc. is committed to revolutionizing the treatment landscape for rare diseases affecting both pediatric and adult populations. The company boasts three approved medications: LIVMARLI® (maralixibat) oral solution, CHOLBAM® (cholic acid) capsules, and CHENODAL® (chenodiol) tablets.

LIVMARLI, an IBAT inhibitor, has garnered approval for alleviating cholestatic pruritus in Alagille syndrome patients in various regions globally. Mirum has also submitted LIVMARLI for regulatory approval in the U.S. and Europe for treating cholestatic pruritus in PFIC patients. CHOLBAM is FDA-approved for managing bile acid synthesis disorders and peroxisomal disorders, while CHENODAL has received FDA recognition for treating patients with cerebrotendinous xanthomatosis (CTX).

Mirum’s advanced pipeline features two investigational treatments for debilitating liver conditions. Volixibat, an IBAT inhibitor, is undergoing evaluation in potentially registrational studies including the Phase 2b VISTAS study for primary sclerosing cholangitis and Phase 2b VANTAGE study for primary biliary cholangitis. Additionally, CHENODAL has demonstrated promising outcomes in a Phase 3 clinical trial, RESTORE, for patients with CTX, with positive topline results reported in 2023.

For more information about Mirum Pharmaceuticals, please visit mirumpharma.com and follow Mirum on social media platforms including Facebook, LinkedIn, Instagram, and Twitter.

Source Link:

Newsletter Updates

Enter your email address below and subscribe to our newsletter